Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2NJW1Vi
via IFTTT